改变错配修复缺陷型结肠癌患者的治疗模式：免疫疗法是否能发挥作用？ - Suppr

Suppr

超能文献

Shifting the treatment paradigm for patients with deficient mismatch repair colon cancer: is there a role for immunotherapy?

作者信息

Kong Joseph C, Flood Michael, Ramsay Robert G, Warrier Satish K, Heriot Alexander

机构信息

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

出版信息

ANZ J Surg. 2021 May;91(5):778-780. doi: 10.1111/ans.16485.

DOI:10.1111/ans.16485

PMID:33999535

Abstract

摘要

相似文献

Shifting the treatment paradigm for patients with deficient mismatch repair colon cancer: is there a role for immunotherapy?

ANZ J Surg. 2021 May;91(5):778-780. doi: 10.1111/ans.16485.

Neoadjuvant immunotherapy for mismatch repair-deficient colon cancer: a phase II study.

Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):534. doi: 10.1038/s41575-024-00966-5.

COL10A1 is a potential immunotherapy biomarker associated with immune infiltration and deficient mismatch repair in colon cancer.

Immunotherapy. 2023 Oct;15(15):1293-1308. doi: 10.2217/imt-2023-0096. Epub 2023 Aug 10.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

Research Perspective on: Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair-Deficient Locally Advanced Colon Cancer: An Emerging Strategy.

Dis Colon Rectum. 2024 Jun 1;67(6):772. doi: 10.1097/DCR.0000000000003325. Epub 2024 May 2.

Will Immune Checkpoint Inhibitors Allow the Non-operative Management of Mismatch Repair-deficient Colorectal Cancer to Become a Standard of Care?

Clin Oncol (R Coll Radiol). 2024 Mar;36(3):136-140. doi: 10.1016/j.clon.2024.01.006. Epub 2024 Jan 14.

Clinical importance of DNA repair in sporadic colorectal cancer.

Crit Rev Oncol Hematol. 2018 Jun;126:168-185. doi: 10.1016/j.critrevonc.2018.03.017. Epub 2018 Mar 29.

Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients.

Dig Liver Dis. 2013 Mar;45(3):245-50. doi: 10.1016/j.dld.2012.09.013. Epub 2012 Oct 24.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

Bull Cancer. 2019 Feb;106(2):137-142. doi: 10.1016/j.bulcan.2018.09.004. Epub 2018 Oct 14.

A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.

Cancer Treat Rev. 2021 Apr;95:102174. doi: 10.1016/j.ctrv.2021.102174. Epub 2021 Mar 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Shifting the treatment paradigm for patients with deficient mismatch repair colon cancer: is there a role for immunotherapy?

作者信息

Kong Joseph C, Flood Michael, Ramsay Robert G, Warrier Satish K, Heriot Alexander

机构信息

Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

出版信息

ANZ J Surg. 2021 May;91(5):778-780. doi: 10.1111/ans.16485.

DOI:10.1111/ans.16485

PMID:33999535

Abstract

摘要

相似文献

Shifting the treatment paradigm for patients with deficient mismatch repair colon cancer: is there a role for immunotherapy?

ANZ J Surg. 2021 May;91(5):778-780. doi: 10.1111/ans.16485.

Neoadjuvant immunotherapy for mismatch repair-deficient colon cancer: a phase II study.

Nat Rev Gastroenterol Hepatol. 2024 Aug;21(8):534. doi: 10.1038/s41575-024-00966-5.

COL10A1 is a potential immunotherapy biomarker associated with immune infiltration and deficient mismatch repair in colon cancer.

Immunotherapy. 2023 Oct;15(15):1293-1308. doi: 10.2217/imt-2023-0096. Epub 2023 Aug 10.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

Research Perspective on: Systematic Review of Neoadjuvant Immunotherapy for Mismatch Repair-Deficient Locally Advanced Colon Cancer: An Emerging Strategy.

Dis Colon Rectum. 2024 Jun 1;67(6):772. doi: 10.1097/DCR.0000000000003325. Epub 2024 May 2.

Will Immune Checkpoint Inhibitors Allow the Non-operative Management of Mismatch Repair-deficient Colorectal Cancer to Become a Standard of Care?

Clin Oncol (R Coll Radiol). 2024 Mar;36(3):136-140. doi: 10.1016/j.clon.2024.01.006. Epub 2024 Jan 14.

Clinical importance of DNA repair in sporadic colorectal cancer.

Crit Rev Oncol Hematol. 2018 Jun;126:168-185. doi: 10.1016/j.critrevonc.2018.03.017. Epub 2018 Mar 29.

Deficient mismatch repair phenotype is a prognostic factor for colorectal cancer in elderly patients.

Dig Liver Dis. 2013 Mar;45(3):245-50. doi: 10.1016/j.dld.2012.09.013. Epub 2012 Oct 24.

Immunotherapy and metastatic colorectal cancers with microsatellite instability or mismatch repair deficiency.

Bull Cancer. 2019 Feb;106(2):137-142. doi: 10.1016/j.bulcan.2018.09.004. Epub 2018 Oct 14.

Cancer Treat Rev. 2021 Apr;95:102174. doi: 10.1016/j.ctrv.2021.102174. Epub 2021 Mar 1.